
Benzinga Pro data, CASI Pharmaceuticals (NASDAQ:CASI) reported Q1 sales of $9.06 million. Earnings fell to a loss of $8.40 million, resulting in a 55.7% decrease from last quarter. CASI Pharmaceuticals collected $9.16 million in revenue during Q4, but reported earnings showed a $5.39 million loss.